Updated Review
Published: April 18, 2022
Since October 2020 (the date of our last update), we found no new publications that warrant TOE grade changes or changes to our conclusions.
Updated Review
Published: October 12, 2020
a. "Since our review, we found a paper suggesting that serum IGF-1 concentrations in PALS were related to their survival (Sci Rep 2020;10:736). Thus, we change our "Mechanisms" grade from "D" to "C." We found another relevant preclinical study showing that this drug can help a mouse model of motor neuron disease (Mol Med 2012;18:1261-1268). There are now multiple well-designed studies showing benefit of this or similar drugs in pre-clinical motor neuron disease models. Thus, we change our preclinical grade from "B" to "A." Unfortunately, we found no new human cases or trials suggesting benefit. Thus, our conclusion is unchanged as follows:
"There remains no convincing evidence that any form of IGF-1, including Iplex can significantly slow progression in human ALS. We do not recommend that PALS pursue off-label IGF-1 in any form at this time outside of a well- designed trial."
Key Information
Click on any letter grade below for more info:
Mechanism Grade: C
Preclinical Trials Grade: A
Cases Grade: B
Trials Grade: D
Risks Grade: F
Published: Aug 2009
The ALSUntangled program is off to a good start, with a number of specific requests from PALS being investigated by a multi-national group of ALSclinician-scientists. PALS and other clinician-scientists who want to become involved in ALSUntangledcan find instructions online (16)